Page last updated: 2024-12-08
norfentanyl
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
norfentanyl: metabolite of fentanyl; RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
norfentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of 4-(N'-phenyl)piperidin-4-amine with propanoic acid. A major metabolite of fentanyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 259381 |
| CHEMBL ID | 3560524 |
| CHEBI ID | 62685 |
| SCHEMBL ID | 926462 |
| MeSH ID | M0214216 |
Synonyms (61)
| Synonym |
|---|
| nsc-89293 |
| 1609-66-1 |
| nsc89293 |
| nsc 89293 |
| 2mk6d8jv6j , |
| unii-2mk6d8jv6j |
| einecs 216-543-3 |
| n-phenyl-n-piperidin-4-ylpropionamide |
| STL301636 |
| norfentanyl |
| AKOS000270694 |
| n-phenyl-n-piperidin-4-ylpropanamide |
| n-phenyl-n-(4-piperidinyl)propanamide |
| A3565 |
| n-phenyl-n-piperidin-4-yl-propionamide |
| n-phenyl-n-(piperidin-4-yl)propionamide |
| 4-(n-propionylanilino)piperidine |
| n-phenyl-n-(piperidin-4-yl)propanamide |
| n-phenyl-n-4-piperidinylpropanamide |
| CHEBI:62685 , |
| n-phenyl-n-4-piperidinylpropionamide |
| 4-(n'-phenyl-n'-propionyl)aminopiperidine |
| BP-10073 |
| n-phenyl-n-(4-piperidinyl)propionamide |
| AB03926 |
| EPITOPE ID:153544 |
| n-(piperidin-4-yl)-n-phenylpropionamide |
| 4-(n-propionanilido)piperidine |
| propanamide, n-phenyl-n-4-piperidinyl- |
| fentanyl citrate impurity b [ep impurity] |
| 4-(n-propionylaniline)piperidine |
| fentanyl impurity b [ep impurity] |
| NCGC00262951-01 |
| cas-1609-66-1 |
| dtxcid3031446 |
| tox21_113943 |
| dtxsid2057657 , |
| 4-[(1-oxopropyl)phenylamino]-piperidine |
| 4-(n-phenyl n-propionylamino) piperidine |
| 4(n-phenyl n-propionylamino) piperidine |
| 4-(n'-phenyl-n'-propionylamino)-piperidine |
| SCHEMBL926462 |
| n-phenyl-n-(4-piperidinyl)propanamide # |
| CHEMBL3560524 , |
| n-phenyl-n-4-piperidinyl-propanamide |
| AC-9332 |
| fentanyl-m nor |
| bdbm50505668 |
| fentanyl imp. b (ep); n-phenyl-n-(piperidin-4-yl)propanamide; norfentanyl; fentanyl citrate impurity b; fentanyl impurity b; fentanyl impurity b |
| norfentanyl (n-phenyl-n-(piperidin-4-yl)propanamide) 1.0 mg/ml in methanol |
| n-phenyl-n-(piperidin-4-yl)propanamide drug precursor |
| J-009767 |
| FT-0716087 |
| SY109619 |
| mfcd00145005 |
| 4-(n-phenylpropionamido)piperidine |
| n-phenyl-n-(4-piperidiny)propanamide |
| Q27132084 |
| AS-30693 |
| norfentanyl monohydrate |
| BAA60966 |
Research Excerpts
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norfentanyl has been identified previously as a urinary metabolite of fentanyl. " | ( Biotransformation of tritiated fentanyl in human liver microsomes. Monitoring metabolism using phenylacetic acid and 2-phenylethanol. Guengerich, FP; Tateishi, T; Wood, AJ; Wood, M, 1995) | 1.73 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "Plasma fentanyl and norfentanyl concentrations and pharmacokinetic parameters did not differ between younger and older subjects." | ( Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Hoffer, C; Kharasch, ED; Whittington, D, 2004) | 0.65 |
| " Pharmacokinetic parameters were calculated using compartmental methods." | ( Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Laine, K; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2008) | 0.35 |
| " The fentanyl concentrations derived by both methods were compared by linear regression and pharmacokinetic analysis." | ( Comparison of liquid chromatography-mass spectrometry and radioimmunoassay for measurement of fentanyl and determination of pharmacokinetics in equine plasma. Mama, KR; Stanley, SD; Thomasy, SM, ) | 0.13 |
| " To facilitate pharmacokinetic studies of fentanyl and its metabolites in neonates and other children, we developed and validated an LC-MS/MS method based on minimally invasive, low blood volume sampling." | ( A low blood volume LC-MS/MS assay for the quantification of fentanyl and its major metabolites norfentanyl and despropionyl fentanyl in children. Christians, U; Clavijo, CF; Cromie, M; Galinkin, JL; Hoffman, KL; Schniedewind, B; Thomas, JJ, 2011) | 0.59 |
| " However there is great interpatient variation in the dose required to relieve pain and little knowledge about the pharmacokinetic and pharmacodynamic (PK/PD) relationship of fentanyl and pain control." | ( Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer. Bista, SR; Good, P; Hardy, J; Haywood, A; Lobb, M; Norris, R; Tapuni, A, 2015) | 0.42 |
| " The simultaneous quantification of morphine, fentanyl and its metabolites via this simple and time- and cost-efficient method could be successfully applied to samples taken for pharmacokinetic evaluation (antemortem and postmortem) after a single dose of morphine or co-administration of morphine with other drugs (e." | ( Determination of Morphine, Fentanyl and Their Metabolites in Small Sample Volumes Using Liquid Chromatography Tandem Mass Spectrometry. Gleba, J; Kim, J, 2020) | 0.56 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 microg/kg), dosed 1 hour after oral quinidine (600 mg) or placebo." | ( Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. Altuntas, TG; Hoffer, C; Kharasch, ED; Whittington, D, 2004) | 0.32 |
| " No change in OTF dosing in the elderly would appear necessary because of altered pharmacokinetics." | ( Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Hoffer, C; Kharasch, ED; Whittington, D, 2004) | 0.32 |
| " Clinically fentanyl dosage adjustments may become necessary when ketoconazole or other strong CYP3A inhibitors are given simultaneously." | ( Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. Haefeli, WE; König, SK; Mahlke, NS; Mikus, G; Skopp, G; Ziesenitz, VC, 2015) | 0.42 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
| Role | Description |
|---|---|
| opioid analgesic | A narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood. |
| drug metabolite | null |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (3)
| Class | Description |
|---|---|
| anilide | Any aromatic amide obtained by acylation of aniline. |
| piperidines | |
| monocarboxylic acid amide | A carboxamide derived from a monocarboxylic acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (4)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 38.9018 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 15.4871 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 (µMol) | 117.7400 | 0.2100 | 5.5537 | 10.0000 | AID1526751 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Other Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | Km | 7.7000 | 0.4770 | 4.0308 | 9.0000 | AID1526737 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (37)
Molecular Functions (19)
Ceullar Components (11)
Bioassays (41)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1526742 | Substrate activity at human OCT3 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis based Michaelis-Menten plot analysis relative to control empty vector transfected cells | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526733 | Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.5 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526737 | Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis based Michaelis-Menten plot analysis relative to control empty vector transfected cells | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526741 | Substrate activity at human OCT3 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis based Michaelis-Menten plot analysis relative to control empty vector transfected cells | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526752 | Passive membrane permeability by LC-MS/MS analysis based PAMPA | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526751 | Inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526732 | Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.1 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526736 | Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis based Michaelis-Menten plot analysis relative to control empty vector transfected cells | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526731 | Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.05 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| AID1526734 | Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.05 to 0.5 uM incubated for 2 mins in presence of 2 mM MPP+ by LC-MS/MS analysis relative to control empty vector transfected cells | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (75)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (8.00) | 18.2507 |
| 2000's | 14 (18.67) | 29.6817 |
| 2010's | 34 (45.33) | 24.3611 |
| 2020's | 21 (28.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (9.09%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 6 (7.79%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 64 (83.12%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||